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Abstract
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This study used high-performance affinity chromatography (HPAC) to examine the binding of
gliclazide (i.e., a sulfonylurea drug used to treat diabetes) with the protein human serum albumin
(HSA) at various stages of modification due to glycation. Frontal analysis conducted with small
HPAC columns was first used to estimate the number of binding sites and association equilibrium
constants (Ka) for gliclazide with normal HSA and glycated HSA. Both normal and glycated HSA
interacted with gliclazide according to a two-site model, with a class of high affinity sites (average
Ka, 7.1-10 × 104 M−1) and a group of lower affinity sites (average Ka, 5.7-8.9 × 103 M−1) at pH
7.4 and 37°C. Competition experiments indicated that Sudlow sites I and II of HSA were both
involved in these interactions, with the Ka values for gliclazide at these sites being 1.9 × 104 M−1
and 6.0 × 104 M−1, respectively, for normal HSA. Two samples of glycated HSA had similar
affinities to normal HSA for gliclazide at Sudlow site I, but one sample had a 1.9-fold increase in
affinity at this site. All three glycated HSA samples differed from normal HSA in their affinity for
gliclazide at Sudlow site II. This work illustrated how HPAC can be used to examine both the
overall binding of a drug with normal or modified proteins and the site-specific changes that can
occur in these interactions as a result of protein modification.
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Introduction
The American Diabetes Association reports that an estimated 25.8 million children and
adults in the U.S. have diabetes, representing almost 8.3% of the population [1]. Diabetes is
a health condition that is related to insulin deficiency or a resistance to insulin. This disorder
results in an increased level of glucose in blood. There are two main types of diabetes. Type
I diabetes (i.e., juvenile or insulin-dependent diabetes) is caused when the immune system
attacks pancreatic beta cells and results in little or no production of insulin. These patients
require insulin for treatment. Type II diabetes (i.e., non-insulin dependent or adult onset
diabetes) is the most common type of diabetes and is created by insulin resistance [1].
Type II diabetes is frequently treated by using sulfonylurea drugs [2]. Sulfonylurea drugs
increase the amount of insulin that is released from beta cells in the pancreas, which helps
*
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control the buildup of glucose in blood. Gliclazide (see Figure 1) is a second generation
sulfonylurea drug that is taken orally. Second-generation sulfonylurea drugs like gliclazide
have a better effectiveness than first-generation sulfonylurea drugs (e.g., acetohexamide and
tolbutamide) in the treatment of diabetes and are more easily excreted by the body [3].
Sulfonylureas such as gliclazide are known to be tightly bound to serum proteins when these
drugs are in blood. The most abundant serum protein is human serum albumin (HSA)
[4-10], which is also the main carrier protein for sulfonylurea drugs in the circulation [4].
HSA has a mass of 66.5 kDa and has two major binding sites for drugs: Sudlow sites I and II
[4]. Sudlow site I is located in subdomain IIA of HSA and is known to bind a variety of
drugs, such as warfarin, azapropazone, phenylbutazone, and salicylate [5]. Sudlow site II is
in subdomain IIIA of HSA and has been shown to bind to ibuprofen, fenoprofen, ketoprofen,
benzodiazepines, and L-tryptophan [5]. Both Sudlow sites I and II have also been found to
bind to the first-generation sulfonylurea drugs acetohexamide and tolbutamide [6,7].
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Glycation is a type of protein modification that is believed to alter the interactions of some
drugs with HSA. Glycation occurs when the presence of glucose in blood leads to the nonenzymatic addition of glucose with proteins. This process initially occurs through a reaction
between glucose or a reducing sugar and a free amine group on a protein (see Figure 2)
[8-13]. Normal individuals have 6-13% of their HSA in a form that is glycated in blood
[8,9,11]. A person with diabetes has approximately 20-30% or more of their HSA in a
glycated form [8,9,11]. In addition, it is known that both Sudlow sites I and II can be
modified as a result of glycation [8-13] and that this modification can affect the binding of
first-generation sulfonylurea drugs at these sites [6,7]. Although the pharmacokinetics and
overall serum protein binding of gliclazide has been previously examined for healthy and
diabetic subjects [14,15], no detailed information was provided in this prior work on the
strength of this binding with HSA or on the effects of glycation on gliclazide-HSA
interactions.
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The purpose of this study will be to use high-performance affinity chromatography (HPAC)
to examine the binding of gliclazide to normal HSA and HSA that has been modified in
vitro to contain various stages of glycation [16-18]. HPAC is a type of HPLC that uses an
immobilized biological molecule (e.g., HSA) as the stationary phase [16]. It is known from
prior work that HPAC can be used with HSA columns to provide precise and fast
measurements of drug-protein interactions with results that give good agreement with those
obtained for soluble HSA [17]. Other advantages of using HPAC for this type of research
are its ease of automation and its ability to use the same preparation of a protein for
hundreds of experiments [16-18]. Recent work with HPAC as a screening method has
indicated that significant changes can occur in the binding of gliclazide with HSA during
glycation, resulting in trends similar to those seen for acetohexamide and tolbutamide [19].
This current study will examine these interactions in a quantitative manner by first using the
method of frontal analysis (or frontal affinity chromatography) to determine the overall
equilibrium constants and binding capacities for gliclazide with normal HSA and glycated
HSA. Competition studies will then be conducted to examine the specific binding of
gliclazide at Sudlow sites I and II on HSA at various stages of glycation. The results should
be useful in determining how glycation can affect the binding of gliclazide, and related
drugs, to HSA during diabetes. This report will also illustrate how HPAC can be used as a
tool to examine the overall binding and site-selective interactions of drugs or other solutes
with modified proteins.
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The gliclazide (≥ 99.9% pure), R-warfarin (≥ 97%), L-tryptophan (≥ 98%), D-(+)-glucose
(99.5%), sodium azide (>95%), HSA (essentially fatty acid free, ≥ 96%), and commercial
sample of in vitro glycated HSA (Lot 058K6087) were from Sigma-Aldrich (St. Louis, MO,
USA). Nucleosil Si-300 (7 μm particle diameter, 300 Å pore size) was obtained from
Macherey-Nagel (Düren, Germany). Reagents for the bicinchoninic acid (BCA) protein
assay were from Pierce (Rockford, IL, USA). A fructosamine assay kit, which was used for
measuring glycation levels, was purchased from Diazyme Laboratories (San Diego, CA,
USA). All aqueous solutions were prepared using water from a Nanopure system
(Barnstead, Dubuque, IA, USA) and were filtered through 0.20 μm GNWP nylon
membranes from Millipore (Billerica, MA, USA).
Instrumentation
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The HPLC system consisted of a DG-2080-53 degasser, two PU-2080 pumps, an AS-2057
autosampler, a CO-2060 column oven, and a UV-2075 absorbance detector from Jasco
(Tokyo, Japan), plus a Rheodyne Advantage PF six-port valve (Cotati, CA, USA).
Chromatograms were collected using EZChrom Elite v3.2.1 (Scientific Software,
Pleasanton, CA, USA) and Jasco LC Net. Non-linear regression was carried out by using
Data Fit 8.1.69 (Oakdale, PA, USA).
Methods
Nucleosil Si-300 silica was converted into a diol-bonded form, and HSA was immobilized
onto the diol-bonded silica through the Schiff base method, as described previously [20-23].
A control support was prepared in the same manner but with no HSA being added during the
immobilization step (Note: Although free amine groups are involved in both the Schiff base
immobilization method and glycation, these processes tend to involve different residues on
HSA [6,7,21]). All supports were downward slurry packed into separate 2.0 cm × 2.1 mm
I.D. columns at 3500 psi (24 MPa). A pH 7.4, 0.067 M potassium phosphate buffer was used
as the packing solution. The columns were stored at 4°C and all experiments were
performed over the course of less than 500 sample applications, with the columns being
routinely washed and used with sterile pH 7.4, 0.067 M phosphate buffer. No significant
changes in binding properties were noted under these conditions during the course of this
study [22].
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A BCA assay was used to directly determine the immobilized protein content for each
support, using HSA or glycated HSA as the standard and the control support as the blank.
The amount of protein in the normal HSA support was 38 (± 3) mg HSA/g silica. Three
glycated HSA supports, each having different levels of modification, were used. The first
glycated HSA sample (gHSA1) was purchased from Sigma and was prepared under
proprietary conditions. The second and third samples (gHSA2 and gHSA3) were prepared in
vitro as described previously [6,7,21] and using conditions similar to those found in the
serum of patients with controlled or advanced diabetes [24]. The amount of protein on these
glycated HSA supports was 29 (± 4), 47 (± 8), or 40 (± 3) mg HSA/g silica, respectively;
this amount corresponded to 10.9-17.6 nmol protein within a 2.0 cm × 2.1 mm I.D. column.
The level of glycation for each HSA sample was determined in replicate through the use of a
fructosamine assay [6,7]. The gHSA1 sample was found by this assay to contain 1.31 (±
0.05) mol hexose/mol HSA and represented mildly glycated HSA, as might be present in
pre-diabetes or early stage diabetes. The gHSA2 sample contained 2.34 (± 0.13) mol hexose/
mol HSA and was representative of many patients with controlled diabetes [26]. The gHSA3
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sample had 3.35 (± 0.14) mol hexose/mol HSA and represented a situation found in patients
with uncontrolled or advanced diabetes [27].
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Solutions of gliclazide, R-warfarin, and L-tryptophan were prepared in pH 7.4, 0.067 M
potassium phosphate buffer. The same buffer was used as the application and elution buffer
in the chromatographic studies. The mobile phases were filtered using a 0.2 μM nylon filter
and degassed for 10-15 min before use. All experiments were carried out at 37°C and 0.5
mL/min, which has been shown in prior work to allow for the measurement of reproducible
retention factors, binding capacities, and association equilibrium constants during frontal
analysis and zonal elution studies for the types of columns that were used in this report
[23,24].
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The columns were first equilibrated with pH 7.4, 0.067 M potassium phosphate buffer. In
the frontal analysis experiments, a switch was then made to the same buffer that contained a
known concentration of gliclazide. Once a breakthrough curve had formed, pH 7.4, 0.067 M
potassium phosphate buffer was then passed again through the column to elute the retained
drug. Concentrations of 1-200 μM gliclazide were used in these experiments and the elution
of gliclazide was monitored at 250 nm. Although gliclazide is a weak acid with a pKa of 5.8
[25], less than a 0.05 unit change in pH occurred when this drug was added to the pH 7.4
phosphate buffer over the entire tested range of gliclazide concentrations. Each frontal
analysis experiment was performed in quadruplicate and the central location of each
breakthrough curve was determined using the equal area method and PeakFit 4.12 (Jandel
Scientific Software, San Rafael, CA, USA) [16]. Based on the results that were obtained for
the control column, a correction was made for non-specific binding of gliclazide to the
support by subtracting the control results from the data for a column containing normal HSA
or glycated HSA. Non-specific binding to the support made up approximately 39% of the
total binding for 1 μM gliclazide on an HSA column and was easily corrected by this
approach, as noted previously for related drugs on similar columns [6,7].
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The zonal elution studies were carried out in quadruplicate using R-warfarin as a sitespecific probe for Sudlow site I and L-tryptophan as a probe for Sudlow site II [5]. During
these experiments, 1-20 μM gliclazide was placed into the mobile phase as 20 μL injections
of 5 μM R-warfarin and L-tryptophan were made (i.e., sample conditions found earlier to
represent linear elution conditions on the types of columns that were examined in this study)
[23]. The elution of R-warfarin or L-tryptophan was monitored at 308 nm or 280 nm,
respectively. Sodium nitrate was injected and monitored at 205 nm as a non-retained solute;
this solute has been found in numerous studies to be a good index of the void volume and
void time for similar HSA columns (e.g., see Refs. [17-24]). Data from the competition
studies were fit to exponentially-modified Gaussian curves and analyzed using PeakFit
v4.12.

Results and Discussion
Frontal analysis studies
The first set of experiments used frontal analysis to examine the overall binding of gliclazide
to samples of either normal or glycated HSA within HPAC columns. This work was used to
provide initial estimates of the association equilibrium constants and moles of binding sites
for gliclazide with these protein preparations. Some typical chromatograms that were
generated for normal HSA during these experiments are given in Figure 3(a). The resulting
data were first analyzed by using a one-site binding model, as represented by Eqs. (1) and
(2) [16-18].
One-site model:
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(1)
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(2)

The term mLapp in Eqs. (1) and (2) represents the apparent moles of the applied analyte (i.e.,
gliclazide) that were required to reach the central point of a breakthrough curve at a given
concentration of analyte in the mobile phase, [A] [17]. The association equilibrium constant
and total moles of binding sites for the analyte in the column are described in Eqs. (1) and
(2) by Ka and mLtot.
Similar equations can be created for systems with multiple binding sites, as shown for a twosite model in Eqs. (3) and (4) [16-18].
Two-site model:
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(3)

(4)

These equations now include two association equilibrium constants (Ka1 and Ka2), which
represent the high and lower affinity sites in the column. The amounts of these two types of
sites, in moles, are described by mL1 and mL2. Eq. (4) includes the term α1, which represents
the fraction all binding sites for an analyte that consist of the high affinity regions (i.e., α1 =
mL1/mLtot). The term β2 in Eq. (4) is the ratio of the association equilibrium constants for the
low versus high affinity sites, or β2 = Ka2/Ka1.
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Figure 3(b) shows a typical binding isotherm that was obtained when the frontal analysis
data for the normal HSA column were examined according to Eq. (1). The use of non-linear
regression gave a best-fit line for Eq. (1) that had a correlation coefficient of 0.998 (n = 10).
The best-fit parameters for this line provided a Ka value of 1.9 (± 0.1) × 104 M−1 and a
value for mLtot of 3.0 (± 0.1) × 10−8 mol. The binding data were also examined by using
double-reciprocal plots of 1/mLapp vs. 1/[A], as illustrated in Figure 4(a) for the normal HSA
column. According to Eq. (2), this type of plot should result in a linear relationship if onesite binding is present between the applied analyte and immobilized binding agent [17]. The
plot that was obtained in this case gave a linear response (correlation coefficient, 0.999 for n
= 7) at the lowest analyte concentrations, or highest values of 1/[A]. However, a small
amount of curvature at lower values of 1/[A] was observed. According to Eq. (4), this
curvature indicates that some multi-site interactions were present.
The linear behavior seen in Figure 4(a) at high values of 1/[A] (or low values of [A]) is
predicted by Eq. (5) [16].
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(5)

It is known from previous work that this linear range will be seen for any system with
multiple and independent binding sites and can be used to estimate the association
equilibrium constant for the highest affinity sites in the system [16]. From this linear range,
an estimate of 3.4 (± 0.1) × 104 M−1 was obtained for the average Ka of gliclazide at its high
affinity sites on HSA.
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Because the plots in Figures 3-4 suggested that multi-site binding was present for gliclazide
with HSA, the frontal analysis data were next examined by using a two-site model. The
resulting fit that was obtained for gliclazide with normal HSA is shown in Figure 4(b). The
two-site model provided a slightly better fit than the one-site model, giving a correlation
coefficient of 0.999 (n = 10). The better agreement of this fit with the data was more clearly
indicated in the residual plots for Figures 3(b) and 4(b) (see insets), in which the two-site
model gave a more random distribution of data points about the best-fit line. The better fit of
the two-site model was also apparent when comparing the sum of the squares of the
residuals for Figures 3(b) and 4(b), in which the two-site model gave a much smaller value
than the one-site model (i.e., 3.77 × 10−12 vs. 1.34 × 10−9). Similar results were obtained
when examining the binding of gliclazide with a column containing glycated HSA (e.g.,
using a sample of gHSA3). No further improvement in the fit was noted when using a
higher-order model, so a two-site model was utilized in all further binding studies with
gliclazide and normal HSA or glycated HSA. Similar results and conclusions were obtained
based on ultrafiltration experiments that used HSA or glycated HSA in a soluble form for
equivalent binding studies (see Electronic Supplementary Material). However, the HPAC
method required much less protein than the ultrafiltration studies (e.g., 11-18 nmol per
column versus 260-280 nmol for one ultrafiltration measurement) and was capable of
reusing the same columns and proteins for hundreds of experiments [6,7,16-18]. HPAC was
also a much faster method than ultrafiltration for these measurements, providing results
within 4-5 min per drug sample compared to 80-90 min per sample for ultrafiltration (e.g.,
see Figure 3(a) and Electronic Supplementary Material).
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The association equilibrium constants that were obtained by frontal analysis for the two-site
model with gliclazide and normal HSA were 7.1 (± 1.9) × 104 M−1 and 8.9 (± 1.5) × 103
M−1. The corresponding values for glycated HSA, using the gHSA3 column as an example,
were 1.0 (± 0.8) × 105 M−1 and 5.7 (± 3.9) × 103 M−1. A summary of the results that were
obtained at pH 7.4 and 37°C is provided in Table 1. These values were similar to those that
have been reported when using a two-site model to describe the interactions of tolbutamide
and acetohexamide with normal HSA or glycated HSA [6,7]. The relative amounts of the
two groups of binding sites were estimated to be 7.1 (± 2.2) × 10−9 mol and 2.7 (± 0.1)
×10−8 mol for normal HSA, with values of 5.6 (± 3.8) × 10−9 mol and 2.6 (± 0.4) ×10−8 mol
being obtained for gHSA3. Based on the protein content of the HPAC columns, these results
corresponded to specific activities of 0.50 (± 0.16) and 1.90 (± 0.16) mol/mol normal HSA
or 0.38 (± 0.25) and 1.71 (± 0.29) mol/mol gHSA3. Given the fact that HSA which has been
immobilized by the Schiff base method is roughly 50-60% active, these results and those
obtained by ultrafiltration (see Electronic Supplementary Material) indicated that 1-2 major
binding sites and 2-3 or more weaker binding regions were involved in the interactions of
gliclazide with normal HSA or glycated HSA. Similar conclusions have been reached when
examining the interactions of acetohexamide and tolbutamide by this approach with normal
HSA or glycated HSA [6,7].
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Zonal elution studies with gliclazide at Sudlow site I
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Competition studies based on zonal elution experiments were next used with the HPAC
columns to identify specific sites for gliclazide on normal HSA and glycated HSA. These
experiments were first conducted by using R-warfarin as a site-selective probe for Sudlow
site I. This region was of interest because it has recently been proposed to be one of high
affinity sites on HSA for sulfonyurea drugs such as acetohexamide and tolbutamide, as
determined through zonal elution studies [6,7]. A typical set of chromatograms for this type
of experiment is shown in Figure 5, in which a small amount of R-warfarin was injected into
the presence of mobile phases that contained various concentrations of gliclazide as a
competing agent. Sodium nitrate was also injected as a non-retained solute to determine the
void time, which was then used to calculate the retention factor (k) for R-warfarin.
Eq. (6) can be used in this type of experiment to describe a system in which direct
competition at a single-site is involved in the binding of the injected probe A and the
competing agent I that has been added to the mobile phase [7].

(6)
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The terms KaA and KaI in Eq. (6) represent the association equilibrium constants for the
probe and competing agent, respectively, and VM is the void volume. According to Eq. (6), a
plot of 1/k versus the competing agent concentration [I] should produce a linear relationship
for a system with single-site competition [7]. The value of KaI can be obtained from this plot
by determining the ratio of the slope to the intercept. In this way it is possible to specifically
examine the binding of the mobile phase additive I at its site of competition with the injected
probe.
As shown in Figure 6(a), a linear fit to Eq. (6) was obtained for gliclazide on each column
that contained normal HSA or glycated HSA when R-warfarin was used as an injected probe
for Sudlow site I. The best-fit lines for these plots had correlation coefficients in the range of
0.960 to 0.998 (n = 5-6). The corresponding residual plots gave only random variations in
the data about the best-fit lines, and the sums of the squares for the residuals were between
1.0 × 10−5 and 1.7 × 10−3. All of these results confirmed that gliclazide and R-warfarin had
direct competition at Sudlow site I on both normal HSA and glycated HSA. Binding at
Sudlow site I has also been noted for acetohexamide and tolbutamide on normal HSA and
glycated HSA [6,7].
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The association equilibrium constants for gliclazide at Sudlow site I, as represented in this
case by KaI in Eqn. (6), where determined on the various HSA columns from the best-fit
lines in Figure 6(a). The results that were obtained at pH 7.4 and 37°C are summarized in
Table 2. An association equilibrium constant of 1.9 (± 0.1) × 104 M−1 was measured for
gliclazide with normal HSA. This result is slightly lower than the Ka values of 4.2-5.5 × 104
M−1 that have been reported for tolbutamide and acetohexamide at the same site on normal
HSA [6,7].
A comparison was next made in the association equilibrium constants that were determined
for gliclazide at Sudlow site I in going from normal HSA to the glycated HSA samples.
There was no significant difference in the Ka values for normal HSA and gHSA1 or gHSA3.
However, there was a 1.9- to 2.0-fold increase in the Ka for gliclazide at Sudlow site I in
going from normal HSA or gHSA1 to gHSA2 and a similar decrease in affinity in going
from gHSA2 to gHSA3. These differences were all significant at the 95% confidence level.
This change in affinity with the level of glycation for HSA has also been noted for
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acetohexamide and tolbutamide, although the degree and direction of this change does vary
from one type of sulfonylurea drug to the next [6,7]. It has been proposed in earlier work
that these alterations in affinity are related to the extent and types of glycation products that
form at or near Sudlow site I as the level of HSA glycation is altered [6,7,28,29].
Zonal elution studies with gliclazide at Sudlow site II
Competition studies on the HPAC columns were also carried out using L-tryptophan as a
site-selective probe for Sudlow site II. This site was of interest because it also has been
demonstrated to be one of high affinity sites on HSA for acetohexamide and tolbutamide
[6,7]. The results of these experiments were again plotted and analyzed through the use of
Eq. (6). All of the normal HSA or glycated HSA columns gave a linear response to this
equation, as illustrated in Figure 6(b), with correlation coefficients that ranged from 0.967 to
0.996 (n = 5-6). The corresponding residual plots all gave a random distribution of the data
points about the best-fit lines and the sum of the squares of the residuals for these best-fit
lines ranged from 4.3 × 10−4 to 1.7 × 10−4. The agreement of these plots with the behavior
predicted by Eq. (6) indicated that gliclazide and L-tryptophan had direct competition at
Sudlow site II. The same conclusion has been reached when the same approach was used to
examine the binding of acetohexamide and tolbutamide at Sudlow site II [6,7].
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The results from the plots in Figure 6(b) were used to determine the association equilibrium
constants for gliclazide at Sudlow site II on each normal HSA or glycated HSA column.
These results are included in Table 2. The Ka value of 6.0 (± 0.5) × 104 M−1 that was
determined for gliclazide at Sudlow site II on normal HSA at pH 7.4 and 37°C agreed with
the average association equilibrium constant that was estimated by frontal analysis for the
high affinity sites of gliclazide on this protein. In addition, the Ka determined for gliclazide
at Sudlow site II on normal HSA was slightly lower than the affinities of 5.3-13 × 104 M−1
that have been measured for tolbutamide and acetohexamide at the same site [6,7].
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All of the glycated HSA samples had affinities at Sudlow site II that were in the range of
104-105 M−1 for gliclazide. However, the size of these values varied with the extent of
glycation. For instance, there was a decrease of 1.3-fold in Ka for gliclazide at Sudlow site II
in going from normal HSA to gHSA1. This change was similar to what has been seen for
acetohexamide with the same samples of normal and glycated HSA, in which a 1.6-fold
decrease in affinity was observed [6]. There was a 1.6-fold increase in Ka between gHSA1
and gHSA2, or a 1.3-fold increase between normal HSA and gHSA2. This was followed by
a 2-fold decrease in Ka in going from gHSA2 to gHSA3, or a 1.6-fold decrease between
normal HSA and gHSA3. These differences were all significant at the 95% confidence level.
As stated in the previous section, these changes in affinity with glycation are thought to be
due to differences in the glycation products that are formed at or near specific regions on
HSA as the overall level of glycation for this protein is increased [6,7,28,29].

Concluding remarks
This report used HPAC as a tool to examine the binding of gliclazide to normal HSA and
HSA with various levels of glycation. Frontal analysis experiments indicated that gliclazide
was binding with normal HSA and glycated HSA through a two-site model that involved
both high and lower affinity sites. There were one or two high affinity regions with an
average association equilibrium constant of approximately 7.1-10 × 104 M−1 and two or
more low affinity sites with an average association equilibrium constant of 5.7-8.9 × 103
M−1 at pH 7.4 and 37°C.
Zonal elution studies demonstrated that gliclazide was binding to both Sudlow sites I and II
in normal HSA and glycated HSA. The association equilibrium constants for these sites
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were in the range of 104-105 M−1. The binding of gliclazide at Sudlow sites I and II for
normal HSA gave association equilibrium constants of 1.9 × 104 M−1 and 6.0 × 104 M−1,
respectively. Two of the glycated HSA samples (i.e., gHSA1 and gHSA3) had similar
affinities to normal HSA for gliclazide at Sudlow site I; however, one of the protein samples
(gHSA2) had a 1.9-fold increase in affinity for gliclazide at this site. All of the glycated
HSA samples differed from normal HSA in their affinity for gliclazide at Sudlow site II.
These data indicate that modifications due to glycation can have different effects on the
interactions of gliclazide with HSA at separate binding sites on this protein. These results
are in agreement with previous data that have been obtained with acetohexamide and
tolbutamide [6,7] and with structural studies that have examined the glycation products that
can form at or near Sudlow sites I and II [28,29]. Similar studies with in vivo glycated HSA
are now in progress to further characterize these effects and to determine their possible
clinical significance.

NIH-PA Author Manuscript

The experiments in this report illustrated how HPAC could be used to provide detailed
information on the binding of a drug or solute with a modified protein. This included data on
the overall model, equilibrium constants and amount of binding sites for a drug-protein
interaction. It was also demonstrated how HPAC can be used to examine the changes in
interactions that occur at specific regions on a protein (e.g., Sudlow sites I and II of HSA).
The methods used in this study were relatively fast (i.e., taking only minutes per sample)
and were easily automated. The small amounts of protein in the HPAC columns and the
ability to reuse these columns for hundreds of binding experiments made this approach more
attractive than ultrafiltration for work with valuable or limited samples of modified proteins.
The techniques used in this study are not limited to gliclazide and normal HSA or glycated
HSA but could be used with many other types of biological interactions. These features
should result in the further use of HPAC for biointeraction analysis.
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Figure 1.

Structure of gliclazide.
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Figure 2.

General reactions involved in the glycation of HSA.
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Figure 3.

(a) Example of frontal analysis studies for gliclazide on a normal HSA column and (b) a
binding isotherm that was generated from such a study. The results in (a) were obtained at
gliclazide concentrations of 200, 100, 50, 20, 10, and 5 μM (top-to-bottom). The best-fit line
in (a) was generated by using Eq. (1) and a one-site model; further details on this fit are
given in the text. The inset in (b) shows the corresponding residual plot.
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Figure 4.

(a) A double-reciprocal plot for data obtained from frontal analysis experiments that
examined the binding of gliclazide with normal HSA, and (b) analysis of the binding
isotherm for gliclazide and normal HSA when using a two-site model. The best-fit line in (a)
was generated by using the data at 10-200 μM gliclazide to the right of this plot. The inset in
(a) shows the small deviations from linearity that occurred at low values of 1/[Gliclazide].
The inset in (b) provides the residual plot for the fit of a two-site model to the frontal
analysis data.
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Figure 5.
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Typical zonal elution competition studies on a normal HSA column using R-warfarin as an
injected site-specific probe and gliclazide as a mobile phase additive. The results in (a) are
for gliclazide concentrations of 20, 10, 5, 1 or 0 μM (top to bottom). The vertical dashed line
is shown for reference and demonstrates how the retention time for the injected probe
changed as the concentration of gliclazide was varied in the mobile phase.

NIH-PA Author Manuscript
Anal Bioanal Chem. Author manuscript; available in PMC 2012 November 1.

Matsuda et al.

Page 16

NIH-PA Author Manuscript
NIH-PA Author Manuscript

Figure 6.

Plots prepared according to Eq. (6) that showing how the reciprocal of the retention factor
for (a) R-warfarin or (b) L-tryptophan changed on HSA or glycated HSA columns as the
concentration of gliclazide was varied in the mobile phase. These results are for normal
HSA (◆), gHSA1 (■), gHSA2 (▲), and gHSA3 (●).
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Table 1

Best-fit parameters obtained for a two-site model for the binding of gliclazide with normal HSA and gHSA3 at
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a

pH 7.4 and 37°C
Type of HSA

Ka1 (× 104 M−1)

mL1 (× 10−9 mol)

Ka2 (× 104 M−1)

mL2 (× 10−9 mol)

Normal HSA

7.1 (± 1.9)

7.1 (± 2.2)

0.89 (± 0.15)

27 (± 1)

gHSA3

10.0 (± 0.8)

5.6 (± 3.8)

0.57 (± 0.39)

26 (± 4)

a

The values in parentheses represent a range of ±1 S.D., as based on error propagation and the precisions of the best-fit slopes and intercepts
obtained when using Eq. (3) for n = 10.
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Table 2

Association equilibrium constants measured at pH 7.4 and 37 °C for gliclazide at Sudlow sites I and II for
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a

normal HSA and in vitro glycated HSA
Type of HSA

Sudlow Site I
Ka (× 104 M−1)

Sudlow Site II
Ka (× 104 M−1)

Normal HSA

1.9 (± 0.1)

6.0 (± 0.5)

gHSA1

1.8 (± 0.2)

4.6 (± 0.4)

gHSA2

3.6 (± 0.3)

7.6 (± 0.6)

gHSA3

2.1 (± 0.2)

3.8 (± 0.4)

a

The values in parentheses represent a range of ±1 S.D., as based on error propagation and the precisions of the best-fit slopes and intercepts
obtained when using Eq. (6) for n = 5-6.
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interactions with modified proteins: binding of gliclazide with
glycated human serum albumin
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Ultrafiltration was used as a reference method to examine the binding of gliclazide with
soluble portions of normal HSA or glycated HSA. These experiments were performed using
Centrifree Micropartition devices (30 kDa MW cutoff, 0.15–1.0 mL sample capacity) from
Amicon (Danvers, MA, USA) and a 5702RH temperature-controlled centrifuge from Eppendorf
(New York, NY, USA) equipped with a fixed-angle centrifuge rotor from VWR (West Chester,
PA, USA). The flow-injection analysis system used to analyze the free gliclazide fractions in the
collected filtrates consisted of a DG-2080-53 degasser, a PU-2080 pump, an AS-2057
autosampler, a CO-2060 column oven, and a UV-2075 absorbance detector from Jasco (Tokyo,
Japan). Data from this system were collected using EZChrom Elite v3.2.1 (Scientific Software,
Pleasanton, CA, USA) and Jasco LC Net. Non-linear regression was carried out by using Data
Fit 8.1.69 (Oakdale, PA, USA).
Ultrafiltration was performed on samples that contained 50–950 M gliclazide and 262–
275 M of HSA or glycated HSA (i.e., samples of gHSA3) in pH 7.4, 0.067 M potassium
phosphate buffer.

Each of these samples was placed into a siliconized polypropylene

microcentrifuge tube and incubated at 37ºC for 45 min. Ultrafiltration was carried out by placing
a 1 mL aliquot of each test mixture into a Centrifree micropartition device and spinning this
mixture at 1,500  g for 25 min at 37 ºC. The filtrate was collected and analyzed for its drug
content by injecting 5 L aliquots in triplicate onto the flow-injection analysis system. These
injections were made at 0.5 mL/min and in the presence of pH 7.4, 0.067 M potassium phosphate
buffer at room temperature. The elution of gliclazide was monitored at 227 nm. A correction for
any contaminants or preservatives remaining in the filtrate from the ultrafiltration device was
made by carrying out similar measurements on filtrates for samples that contained only HSA or
glycated HSA but no drug in pH 7.4, 0.067 M potassium phosphate buffer. The presence of non-

specific adsorption between gliclazide and the ultrafiltration membrane was measured by using
samples that contained only gliclazide but no HSA or glycated HSA; these experiments indicated
that less than 1% adsorption was taking place between the ultrafiltration membrane and
gliclazide.
In ultrafiltration, binding isotherms can be described through equations that relate the
concentration of the free or unbound drug in a drug/protein mixture to the association
equilibrium constant and the number of identical and independent sites for the drug-protein
interaction. For example, a system with single-site binding can be described by using the
following equation.

r

n K a [ Df ]
1  K a [ Df ]

(1s)

In this equation, r is the ratio of the concentration of the bound form of the drug versus the total
concentration of the protein, n is the number of identical and independent binding sites for the
drug on the protein, Ka is the association equilibrium constant for the drug-protein interaction
and [Df] is concentration of the free or “unbound” drug. Similar, expanded forms of such a
relationship can be used to describe multi-site binding. A typical binding isotherm that was
obtained when using a two-site model is shown in Figure S1.
When the binding of glicazide with normal HSA was examined using a one-site model,
the association equilibrium constant that was obtained was 9.2 (± 0.8) × 103 M-1 and the
estimated number of binding sites was 3.5 (± 0.1) mol/mol HSA. The correlation coefficient for
this fit was 0.990 (n = 13). The residual plot for this fit gave a non-random distribution of the
data about the best-fit line and a sum of the squares of the residuals of 9.6 ×10-2. It was
concluded from these results that gliclazide was probably binding to normal HSA through a
multi-site model.

When a two-site model was used to examine the ultrafiltration data for gliclazide and
normal HSA, a Ka value of 2.0 (± 0.8)  104 M-1 was obtained for the high affinity site and a
value of n Ka of 3.8 (± 0.1) × 103 M-1 was measured for the low affinity sites. The estimated
number of the high affinity sites was 1.9 (± 0.8) mol/mol HSA. The correlation coefficient for
this fit was 0.999 (n = 13), which represented better fit than that the one-site model. The sum of
the squares of the residuals for the two-site fit was 2.9 ×10-2, and only random variations were
seen in the corresponding residual plot.
Ultrafiltration was next used to look at the binding isotherm for gliclazide and glycated
HSA. The one-site model gave an equilibrium association constant of 1.0 (± 0.1) × 104 M-1 and
a number of binding sites that was equal to 2.9 (± 0.1) mol/mol HSA. The correlation coefficient
for this fit was 0.990 (n = 13). The residual plot showed a non-random distribution with a sum
of the squares of the residuals that was equal to 9.3 × 10-2. A two-site model provided a better fit
for the binding of gliclazide to glycated HSA, giving a correlation coefficient of 0.994 (n = 13).
Only random variations were seen in the corresponding residual plot, and the sum of the squares
of the residuals for the two-site model was 1.7 × 10-3. The estimated value for Ka at the high
affinity sites in the two-site model was 3.0 (± 9.5) × 104 M-1 and the value of n Ka at the low
affinity sites was 4.7 (± 9.0) × 103 M-1.
mol/mol HSA.

The amount of the high affinity sites was 1.3 (± 0.6)

Figure S1.
Fit of ultrafiltration data for gliclazide in the presence of normal HSA when using a two-site model, as represented by
Eq. (1s). The inset shows the corresponding residual plot. The best-fit values that were obtained for the association equilibrium
constant and number of binding sites are presented in the supplemental material. Each point represents the average of three
measurements; the error bars, which represent a range of ± 1 S.D., are comparable in size to the markers used in this plot.

